Evidence map›Paper›PMID 41140671›Full record

ArticleFrontiers in medicine2025

Neoadjuvant chemotherapy impacts axillary lymph node positivity in early breast cancer (cT1-2N0M0) with negative axillary lymph nodes at diagnosis.

Jinxiu Ma, Zhimin Fan, Zhifang Jia, Xiaoxiao Dong, Jian Sun, Xiaozhen Wang

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jinxiu MaDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhimin FanDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhifang JiaDivision of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, Jilin, China.
Xiaoxiao DongDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Jian SunDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Xiaozhen WangDepartment of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study compared the role of neoadjuvant chemotherapy (NAC) followed by surgery vs. upfront surgery for avoiding axillary lymph node dissection (ALND) in patients with cT1-2N0M0 breast cancer and clinically negative axillary lymph nodes (LNs) at diagnosis. Patients and methods: Medical records of a sample of 1,695 patients with a primary diagnosis of axillary LN-negative early-stage breast cancer who underwent surgical treatment for breast cancer at the First Bethune Hospital of Jilin University between June 2019 and December 2022 were retrospectively reviewed. The positive rate of sentinel lymph nodes (PR Results: 15 patients who received NAC followed by surgery and 79 patients who underwent upfront surgery had positive SLNs. Four patients who received NAC followed by surgery and 1 patient who underwent upfront surgery had other positive LNs. Overall, NAC followed by surgery significantly lowered PR Conclusion: NAC may reduce the rate of axillary LN positivity and the likelihood of ALND in patients aged 40-60 years with cT2N0M0 HER2+ breast cancer and clinically negative axillary LNs at diagnosis.

Indexed as

axillary lymph node dissectionbreast cancerinvasive disease-free survivalneoadjuvant chemotherapysentinel lymph node biopsy

Identifiers

PMID41140671
PMCPMC12549614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.